INSM Stock Overview
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases.
Insmed Incorporated Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$27.40|
|52 Week High||US$34.44|
|52 Week Low||US$16.41|
|1 Month Change||18.46%|
|3 Month Change||27.44%|
|1 Year Change||19.70%|
|3 Year Change||62.32%|
|5 Year Change||128.72%|
|Change since IPO||-83.39%|
Recent News & Updates
Insmed rises 16% on better-than-expected Q2 result
Insmed (NASDAQ:INSM) is trading 16% higher after the company reported Q2 result that beat estimates, helped by higher sales of lung disease treatment, Arikayce. Arikayce net sales were $47.2M in the U.S., $15.8M in Japan, and $2.2M in Europe and rest of world. Q2 GAAP EPS of -$0.80 beats by $0.09, while revenue rose 43.6% to $65.2M, and beats by $6.28M. The company continues to expect full-year global revenues for Arikayce to increase at least 30% year over year from 2021 and expects that its cash on hand will support its ongoing business into 2024. Cost of product revenues rose 52% Y/Y to $16.4M.
|INSM||US Biotechs||US Market|
Return vs Industry: INSM exceeded the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: INSM exceeded the US Market which returned -10.2% over the past year.
|INSM Average Weekly Movement||10.0%|
|Biotechs Industry Average Movement||12.6%|
|Market Average Movement||7.7%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: INSM is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: INSM's weekly volatility (10%) has been stable over the past year.
About the Company
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders.
Insmed Incorporated Fundamentals Summary
|INSM fundamental statistics|
Is INSM overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|INSM income statement (TTM)|
|Cost of Revenue||US$52.06m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-3.47|
|Net Profit Margin||-188.04%|
How did INSM perform over the long term?See historical performance and comparison